Carbidopa/levodopa (WD-1603) vs Melevodopa/carbidopa (Sirio)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Carbidopa/levodopa (WD-1603)

Developed by Hong Kong WD Pharmaceutical Co., Limited

Phase 2 in Parkinson's Diseasesmall molecule
Partial signal

NCT05036473 · Phase 2 · completed

This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.

Reported efficacy

To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group. (27 days- from the baseline to the 27th day): Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003) (met)

Result source: NCT05036473

Melevodopa/carbidopa (Sirio)

Marketed by Chiesi Farmaceutici

Phase 1/2 in Parkinson's Diseasesmall molecule
Partial signal

NCT00491998 · Phase 1/2 · completed

The study was randomized and double-blind, with a planned enrollment of 27 participants and a comparison with standard levodopa/carbidopa tablets. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

to characterise the plasma concentrations of L-dopa after repeated doses of V1512 in fluctuating PD patients compared to standard L-dopa/carbidopa (Sinemet) over the course of the day (4 weeks): L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. (not_applicable)

Result source: NCT00491998

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCarbidopa/​levodopa (WD-1603)Melevodopa/​carbidopa (Sirio)
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported

ON time without troublesome dyskinesia, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported

UPDRS Part III, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported

MDS-UPDRS Part II, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Melevodopa/carbidopa (Sirio)
L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. NCT00491998 · Phase 1/2 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Carbidopa/levodopa (WD-1603)

MDS-UPDRS II III -6.7 score @ 3.857142857142857wk
absolute change · score
No placebo or comparator arm
NCT05036473 · Phase 2 · sponsor-reported, not registry data
show 2 more results
-8.5 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data
-13.6 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carbidopa/levodopa (WD-1603)'s landscape · Melevodopa/carbidopa (Sirio)'s landscape